Ysios Capital — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsVida VenturesJeito Capital
Cytoki is a biotech company developing IL-22-based therapeutics using lipidation technology to treat metabolic diseases such as obesity and type 2 diabetes, as well as conditions involving epithelial injury like inflammatory bowel disease.
BiotechHealthtechVærløse, DK
Rasmus Jorgensen(CEO & Founder)
Co-investors+ND CapitalSeventure Partners
InBioMotion offers a biomarker test that analyzes MAF gene levels to assess prognosis and guide personalized bisphosphonate treatment in early breast cancer patients.
BiotechDigital HealthMedical Devices
BoardProf Rob E. Coleman(Chairman)
Co-investorsCriteria Bio VenturesAlta Life SciencesAsabys Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.